Literature DB >> 19013709

Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.

Carolyn E Clark1, Gregory L Beatty, Robert H Vonderheide.   

Abstract

The resurgent theory of cancer immunosurveillance holds that the immune system plays an important role in the suppression of tumors, particularly in the elimination of early neoplastic lesions. Tumors with reduced immunogenicity or those that have acquired mechanisms to suppress immune effector functions, however, can emerge from this selection pressure and grow progressively. This is an especially important issue in pancreatic cancer, which although inflammatory in vivo is nevertheless highly aggressive and nearly always lethal. Here, we review emerging data obtained from novel genetically defined mouse models of pancreatic adenocarcinoma that suggest that the immune system may be complicit in the inception and progression of pancreatic cancer. Host immune cells with suppressive properties infiltrate the pancreas early during tumorigenesis, even at the earliest stages of neoplasia, preceding and effectively undermining any lymphocytes with potential antitumor function. Thus, in pancreatic adenocarcinoma, the failure of immunosurveillance is likely an early event during tumorigenesis, a concept that carries important implications for the design of novel immunotherapeutics in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013709     DOI: 10.1016/j.canlet.2008.09.037

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  80 in total

1.  Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

Authors:  Mariana Malvicini; Mariana Ingolotti; Flavia Piccioni; Mariana Garcia; Juan Bayo; Catalina Atorrasagasti; Laura Alaniz; Jorge B Aquino; Jaime A Espinoza; Manuel Gidekel; O Graciela Scharovsky; Pablo Matar; Guillermo Mazzolini
Journal:  Mol Oncol       Date:  2011-04-05       Impact factor: 6.603

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

3.  Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.

Authors:  David Z Chang; Ying Ma; Baoan Ji; Huamin Wang; Defeng Deng; Yan Liu; James L Abbruzzese; Yong-jun Liu; Craig D Logsdon; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

Review 4.  Current progress in immunotherapy for pancreatic cancer.

Authors:  Kelly Foley; Victoria Kim; Elizabeth Jaffee; Lei Zheng
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

5.  A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.

Authors:  Hayley S Ma; Bibhav Poudel; Evanthia Roussos Torres; John-William Sidhom; Tara M Robinson; Brian Christmas; Blake Scott; Kayla Cruz; Skylar Woolman; Valerie Z Wall; Todd Armstrong; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2019-01-14       Impact factor: 11.151

6.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

Review 7.  CD40 immunotherapy for pancreatic cancer.

Authors:  Robert H Vonderheide; David L Bajor; Rafael Winograd; Rebecca A Evans; Lauren J Bayne; Gregory L Beatty
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

8.  Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Authors:  Pu Liu; Jade Jaffar; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

Review 9.  Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

Authors:  Worta McCaskill-Stevens; Deborah C Pearson; Barnett S Kramer; Leslie G Ford; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

Review 10.  Inflammatory networks and immune surveillance of pancreatic carcinoma.

Authors:  Robert H Vonderheide; Lauren J Bayne
Journal:  Curr Opin Immunol       Date:  2013-02-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.